PACE Trial: Phase II trial of ponatinib in patients with chronic myeloid leukaemia (CML)

Dr Jorge Cortes - MD Anderson Cancer Center, Houston, TX, USA
PACE Trial: Phase II trial of ponatinib in patients with chronic myeloid leukaemia (CML) ( Dr Jorge Cortes - MD Anderson Cancer Center, Houston, TX, USA )
17 Dec 2012

Pomalidomide with low-dose vs. high-dose dexamathasone in refractory patients

Professor Meletios Dimopoulos - University of Athens, Greece
Pomalidomide with low-dose vs. high-dose dexamathasone in refractory patients ( Professor Meletios Dimopoulos - University of Athens, Greece )
16 Dec 2012

MLN9708 in combination with lenalidomide and dexamethasone

Dr Shaji Kumar - Mayo Clinic, Rochester, USA
MLN9708 in combination with lenalidomide and dexamethasone ( Dr Shaji Kumar - Mayo Clinic, Rochester, USA )
16 Dec 2012

History of epidermal stem cell use in the clinical setting

Prof Michele De Luca - University of Modena e Reggio Emilia, Modena, Italy
History of epidermal stem cell use in the clinical setting ( Prof Michele De Luca - University of Modena e Reggio Emilia, Modena, Italy )
14 Dec 2012

Exercise benefit to lifespan may be due to stem cell increase

Dr Mariusz Ratajczak - James Graham Brown Cancer Center, University of Louisville, Kentucky, USA
Exercise benefit to lifespan may be due to stem cell increase ( Dr Mariusz Ratajczak - James Graham Brown Cancer Center, University of Louisville, Kentucky, USA )
14 Dec 2012

Diagnosis of blood cancer after a breast cancer diagnosis

Prof Antonio Wolff - The Johns Hopkins Hospital, Baltimore, USA
Diagnosis of blood cancer after a breast cancer diagnosis ( Prof Antonio Wolff - The Johns Hopkins Hospital, Baltimore, USA )
14 Dec 2012

Histone deacetylases targeted as new strategy against graft versus host disease

Prof Sung Choi - University of Michigan, Ann Arbor, USA
Histone deacetylases targeted as new strategy against graft versus host disease ( Prof Sung Choi - University of Michigan, Ann Arbor, USA )
14 Dec 2012

Ponatinib for CML and Philadelphia chromosome-positive acute lymphoblastic leukaemia

Dr Jorge Cortes - MD Anderson Cancer Center, Houston, TX, USA
Ponatinib for CML and Philadelphia chromosome-positive acute lymphoblastic leukaemia ( Dr Jorge Cortes - MD Anderson Cancer Center, Houston, TX, USA )
13 Dec 2012

Quizartinib for FLT3-ITD positive AML after second-line chemo or stem cell transplant

Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA
Quizartinib for FLT3-ITD positive AML after second-line chemo or stem cell transplant ( Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA )
13 Dec 2012

The BTK inhibitor ibrutinib (PCI-32765) in combination with rituximab

Prof Jan Burger - The University of Texas MD Anderson Cancer Center, Houston, USA
The BTK inhibitor ibrutinib (PCI-32765) in combination with rituximab ( Prof Jan Burger - The University of Texas MD Anderson Cancer Center, Houston, USA )
13 Dec 2012

Uncovering new targets for treatment of chronic lymphocytic leukaemia

Dr John Byrd - The Ohio State University Comprehensive Cancer Center, Columbus, USA
Uncovering new targets for treatment of chronic lymphocytic leukaemia ( Dr John Byrd - The Ohio State University Comprehensive Cancer Center, Columbus, USA )
13 Dec 2012

Targeting the proteasome mechanism

Dr Stig Linder – Karolinska Institute, Stockholm, Sweden
Targeting the proteasome mechanism ( Dr Stig Linder – Karolinska Institute, Stockholm, Sweden )
7 Dec 2012